Thursday, April 22, 2010

Doctor groups set new ethics codes to curb Big Pharma's influence

It's the most sweeping move ever taken by the Council of Medical Specialty Societies to curb conflict of interest — a growing concern as Big Pharma bankrolls a greater share of medical research.

One of its most controversial rules: requiring top leaders of any medical society and top editors of its journals to have no consulting deals or financial ties to industry.

"When a physician stands up to represent medicine and his or her specialty, there shouldn't be any confusion as to who they're speaking for," said Dr. Norman Kahn, the council's chief executive and a former rural medicine doctor from California.

The code requires groups to:

•Publicly post any industry support the group receives, such as money for continuing education sessions.

•Decline industry funding for developing medical practice guidelines, such as who should get a drug, a test or treatment. Require that most members of a guidelines panel be free of financial ties to industry.

•Disclose any financial ties that leaders and board members have with companies.

•Ban company or product names and logos from pens, bags and other giveaways at conferences.

Fourteen groups in the council, including ASCO and the College of Physicians, have already adopted the code. Most of the rest plan to by the end of the year.

Last year, leading medical journals agreed to use a uniform conflict-of-interest disclosure form for researchers publishing in their journals. The new ethics code the council is adopting should make financial ties more transparent to patients and breed professionalism and trust in doctors, Kahn said.

Posted via web from Jack's posterous

1 comment:

Pharma Conduct Guy said...

Great catch Jack Friday!